Publications

 

At SBW, we believe the best way to demonstrate our expertise and validate our methods and services includes a publication in a peer-reviewd scientific journal.

The scope of our contributed publications is indicating our diverse expertise, combining areas of analytical chemistry, molecular biology, biochemistry, cell biology, different disease areas (like CNS and oncology) and ‘omics technologies. We feel that in order to understand the projects at hand and to provide best proposals for each assignment, comprehensive and multidisciplinary expertise is needed in modern drug discovery, rather than just particular narrow analytical expertise. For example, it is a totally different ballgame to develop drugs against cancer than to CNS diseases; not just concerning the target/target classes, but also relating to many ADME properties. Niche specialized CROs, like focusing just on ADME analytics aspects, often do not recognize this or try to overlook it, whilst for a successful drug discovery the cross-disciplinarity understanding is vital.

We have given very solid contribution also to papers published in the best ranked journals with impact factors above 25..30. Contribution to such papers shows our commitment to quality instead of aiming at just quantity in low impact rapid journals.

This list includes also articles contributed in the SBW group by people who have since proceeded their careers elsewhere. Some of that appreciated work has remained with SBW as e.g. SOPs in the lab, if not replaced by more modern methods since.

Accepted publications including SBW group employees co-authoring since 2005

  1. Khaled Abass, Petri Reponen, Sampo Mattila, Olavi Pelkonen: Metabolism of α-Thujone in Human Hepatic Preparations in vitro, Xenobiotica 41 (2011) p. 101-111.
  2. Soikkeli A, Kurkela M, Hirvonen J, Yliperttula M, Finel M: Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6. Assay Drug Dev Technol. 2011: 9:496-502.
  3. Lehtonen P, Sten T, Aitio O, Kurkela M, Vuorensola K, Finel M, Kostiainen R. Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol. Eur J Pharm Sci. 2010: 41: 523-30.
  4. Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, Finel M.Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos. 2010: 38:386-95.
  5. Sten T, Kurkela M, Kuuranne T, Leinonen A, Finel M. UDP-glucuronosyltransferases in conjugation of 5alpha- and 5beta-androstane steroids. Drug Metab Dispos. 2009: 37: 2221-7.
  6. Patana AS, Kurkela M, Finel M, Goldman A. Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases. Protein Eng Des Sel. 2008: 21:537-43.
  7. Finel M, Kurkela M. The UDP-glucuronosyltransferases as oligomeric enzymes. Curr Drug Metab. 2008; 9:70-6.
  8. Bichlmaier I, Kurkela M, Siiskonen A, Finel M, Yli-Kauhaluoma J. Eudismic analysis of tricyclic sesquiterpenoid alcohols: lead structures for the design of potent inhibitors of the human UDP-glucuronosyltransferase 2B7. Bioorg Chem. 2007: 35:386-400.
  9. Trubetskoy OV, Finel M, Kurkela M, Fitzgerald M, Peters NR, Hoffman FM, Trubetskoy VS. High throughput screening assay for UDP-glucuronosyltransferase 1A1 glucuronidation profiling. Assay Drug Dev Technol. 2007: 5:343-54.
  10. Patana AS, Kurkela M, Goldman A, Finel M. The human UDP-glucuronosyltransferase: identification of key residues within the nucleotide-sugar binding site. Mol Pharmacol. 2007: 72:604-11.
  11. Bichlmaier I, Kurkela M, Joshi T, Siiskonen A, Rüffer T, Lang H, Finel M, Yli-Kauhaluoma J. Potent inhibitors of the human UDP-glucuronosyltransferase 2B7 derived from the sesquiterpenoid alcohol longifolol. ChemMedChem. 2007: 2:881-9.
  12. Bichlmaier I, Kurkela M, Joshi T, Siiskonen A, Rüffer T, Lang H, Suchanova B, Vahermo M, Finel M, Yli-Kauhaluoma J. Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives. J Med Chem. 2007: 50:2655-64.
  13. Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, Hirvonen J, Goldman A, Finel M. Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenet Genomics. 2007: 17:115-26.
  14. Bichlmaier I, Siiskonen A, Kurkela M, Finel M, Yli-Kauhaluoma J. Chiral distinction between the enantiomers of bicyclic alcohols by UDP-glucuronosyltransferases 2B7 and 2B17. Biol Chem. 2006: 387:407-16.
  15. Kreander K, Kurkela M, Siiskonen A, Vuorela P, Tammela P. Identification of COMT and ErmC inhibitors by using a microplate assay in combination with library focusing by virtual screening. Pharmazie. 2006: 61:247-8.
  16. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M. Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005: 33:1017-26.
  17. Khaled Abass, Petri Reponen, Sampo Mattila, Olavi Pelkonen: Metabolism of α-Thujone in Human Hepatic Preparations in vitro, Xenobiotica 41 (2011) p. 101-111.
  18. Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT. Exposure to Oral S-ketamine Is Unaffected by Itraconazole but Greatly Increased by Ticlopidine. Clin Pharmacol Therap. 90:296-302, 2011.
  19. Alhopuro P, Sammalkorpi H, Niittymäki I, Biström M, Raitila A, Saharinen J, Nousiainen K, Lehtonen HJ, Heliövaara E, Puhakka J, Tuupanen S, Sousa S, Seruca R, Ferreira AM, Hofstra RM, Mecklin JP, Järvinen H, Ristimäki A, Orntoft TF, Hautaniemi S, Arango D, Karhu A, Aaltonen LA. Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer. 2011 May 4.
  20. Abass K, Reponen P, Mattila S, Pelkonen O. Metabolism of α-Thujone in Human Hepatic Preparations in vitro. Xenobiotica. 41: 101-111, 2011.
  21. Alhopuro P, Björklund M, Sammalkorpi H, Turunen M, Tuupanen S, Biström M, Niittymäki I, Lehtonen HJ, Kivioja T, Launonen V, Saharinen J, Nousiainen K, Hautaniemi S, Nuorva K, Mecklin JP, Järvinen H, Orntoft T, Arango D, Lehtonen R, Karhu A, Taipale J, Aaltonen LA. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 8:952-60, 2010.
  22. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O’Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Döring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burtt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA Jr, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466:707-13, 2010.
  23. Lonka-Nevalaita L,  Lume M, Leppänen S, Peränen J, Jokitalo E, Saarma M. Characterization of the intracellular localization, processing, and secretion of two glial cell line-derived neurotrophic factor splice isoforms. J Neuroscience. 30(34): 11403-13, 2010
  24. Alhopuro P, Björklund M, Sammalkorpi H, Turunen M, Tuupanen S, Biström M, Niittymäki I, Lehtonen HJ, Kivioja T, Launonen V, Saharinen J, Nousiainen K, Hautaniemi S, Nuorva K, Mecklin JP, Järvinen H, Orntoft T, Arango D, Lehtonen R, Karhu A, Taipale J, Aaltonen LA. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 8:952-60, 2010
  25. Lagus M, Gass N, Saharinen J, Saarela J, Porkka-Heiskanen T, Paunio T. Gene expression patterns in a rodent model for depression. Eur J Neurosci. 31:1465-73, 2010.
  26. Tritschler I, Gramatzki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, Wick W, Keski-Oja J, Weller M. Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. Int J Cancer.125:530-40, 2009.
  27. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Döring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L; ENGAGE Consortium. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 41:47-55, 2009.
  28. Jakkula E, Rehnström K, Varilo T, Pietiläinen OP, Paunio T, Pedersen NL, deFaire U, Järvelin MR, Saharinen J, Freimer N, Ripatti S, Purcell S, Collins A, Daly MJ, Palotie A, Peltonen L. The genome-wide patterns of variation confirms significant substructure in a founder population. American Journal of Human Genetics. Am J Hum Genet. 12:787-794, 2008.
  29. Petsalo, Aleksanteri, Turpeinen, Miia, Pelkonen, Olavi, Tolonen, Ari. Analysis of nine drugs and their cytochrome P450 specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 µm particle size column. Journal of Chromatography A. In press, 2008.
  30. Ruosaari S, Hienonen-Kempas T, Puustinen A, Sarhadi VK, Hollmén J, Knuutila S, Saharinen J, Wikman H, Anttila, S. Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients. BMC Medical Genomics 1:55, 2008.
  31. Tolonen, Ari, Turpeinen, Miia, Pelkonen, Olavi. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discovery Today. In press, 2008.
  32. Volotinen, Marjo, Mäenpää, Jukka, Kautiainen, Hannu, Tolonen, Ari,  Uusitalo, Jouko, Nilsson, Mats, Ropo, Auli, Vapaatalo, Heikki, Aine, Esko. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor. European Journal of Pharmaceutical Sciences. In press, 2008.
  33. Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen J, Robinson JP, Yang Z, Chen LQ, Orntoft T, Mecklin JP, Järvinen H, Eng C, Moeslein G, Shibata D, Houlston RS, Lucassen A, Tomlinson IP, Launonen V, Ristimäki A, Arango D, Karhu A, Sweeney HL, Aaltonen LA. Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A, 2008. 105(14): p. 5513-8.
  34. Ilmarinen T, Kangas H, Kytömaa T, Eskelin P, Saharinen J, Seeler JS, Tanhuanpää K, Chan FY, Slattery RM, Alakurtti K, Palvimo JJ, Ulmanen I. Functional interaction of AIRE with PIAS1 in transcriptional regulation. Mol Immunol, 2008. 45(7): p. 1847-62.
  35. Korhonen, Tuomas, Turpeinen, Miia, Tolonen, Ari, Laine, Kari, Pelkonen, Olavi. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. Journal of Steroid Biochemistry and Molecular Biology, 2008. 110, 56-66.
  36. Kumar, K.K., Shelokar, P.S. An SVM method using evolutionary information for the identification of allergenic proteins, Bioinformation, 2008. 2(6), 253-256.
  37. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell, 2008. 13(5): p. 407-19.
  38. Pietilainen, K.H., et al. Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med, 2008. 5(3): p. e51.
  39. Pöntynen N, Strengell M, Sillanpää N, Saharinen J, Ulmanen I, Julkunen I, Peltonen L. Critical immunological pathways are downregulated in APECED patient dendritic cells. J Mol Med, 2008.
  40. Pugalenthi, Ganesan K., Kumar, Krishna, Suganthana, P.N., Gangal, Rajeev. Identification of catalytic residues from protein structure using support vector machine with sequence and structural features. Biochem Biophys Res Commun, 2008. Jan 16. [Epub ahead of print].
  41. Scheinin I, Myllykangas S, Borze I, Böhling T, Knuutila S, Saharinen J. CanGEM: mining gene copy number changes in cancer. Nucleic Acids Res, 2008. 36(Database issue): p. D830-5.
  42. von Schantz C, Saharinen J, Kopra O, Cooper JD, Gentile M, Hovatta I, Peltonen L, Jalanko A. Brain gene expression profiles of Cln1 and Cln5 deficient mice unravels common molecular pathways underlying neuronal degeneration in NCL diseases. BMC Genomics, 2008. 9: p. 146.
  43. Heine C, Quitsch A, Storch S, Martin Y, Lonka L, Lehesjoki A-E, Braulke T. Topology and endoplasmic reticulum retention signals of the lysosomal storage disease-related membrane protein CLN6. Mol Membr Biol 1:74-87, 2007.
  44. Karppinen, Katja, Hokkanen, Juho, Tolonen, Ari, Mattila, Sampo, Hohtola, Anja. Biosynthesis of hyperforin and adhyperforin from amino acid precursors in shoot cultures of Hypericum perforatum. Phytochemistry, 2007. 68, 1038 -1045.
  45. Kiialainen A, Veckman V, Saharinen J, Paloneva J, Gentile M, Hakola P, Hemelsoet D, Ridha B, Kopra O, Julkunen I, Peltonen L. Transcript profiles of dendritic cells of PLOSL patients link demyelinating CNS disorders with abnormalities in pathways of actin bundling and immune response. J Mol Med, 2007. 85(9): p. 971-83.
  46. Mundra, Piyush Kumar, Kumar, Madhan, Kumar, K., Kumar, Krishna, Jayaraman, V.K., Kurkarni, B.D. Using Pseudo Amino Acid Composition to Predict Protein Sub nuclear Localization: Approached with PSSM. Pattern Recognition Letters, 2007. 28 1610–1615.
  47. Neural precursor cells from a fatal human motoneuron disease differentiate despite aberrant gene expression. Neural precursor cells from a fatal human motoneuron disease differentiate despite aberrant gene expression. Dev Neurobiol, 2007. 67(3): p. 270-84.
  48. Petsalo, Aleksanteri, Turpeinen, Miia, Tolonen, Ari. Identification of bupropion urinary metabolites by liquid chromatography-mass spectrometry. Rapid Communications in Mass Spectrometry, 2007. 21, 2547-2554.
  49. Raje, Dhananjay, Krishnan, Venkatesh, Bundela, Saurabh, Rekha Rao, M.S. Identification of closely linked SNP markers using information theory. CAMDA, 2007. (Critical Assessment of Microarray Data Analysis).
  50. Turpeinen, Miia, Koivuviita, Niina, Tolonen, Ari, Reponen, Petri, Lundgren, Stefan, Miettunen, Jouko, Metsärinne, Kaj, Rane, Anders, Pelkonen, Olavi, Laine, Kari. Effect of kidney disease on the hepatic cytochrome P450 (CYP) 2B6 activity as measured by bupropion pharmacokinetics. British Journal of Clinical Pharmacology, 2007. 64, 165-173.
  51. Tolonen, Ari, Petsalo, Aleksanteri, Turpeinen, Miia, Uusitalo, Jouko, Pelkonen, Olavi. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with thirteen probe reactions and a single LC/MSMS run; analytical validation and further testing with monoclonal P450 antibodies. Journal of Mass Spectrometry, 2007. 42, 960-966.
  52. Volotinen, Marjo, Turpeinen, Miia, Tolonen, Ari, Uusitalo, Jouko, Mäenpää, Jukka, Pelkonen, Olavi. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metabolism and Disposition, 2007. 35, 1135 – 1141 .
  53. Wick N, Saharinen P, Saharinen J, Gurnhofer E, Steiner CW, Raab I, Stokic D, Giovanoli P, Buchsbaum S, Burchard A, Thurner S, Alitalo K, Kerjaschki D. Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro. Physiol Genomics, 2007. 28(2): p. 179-92.
  54. Wikman H, Ruosaari S, Nymark P, Sarhadi VK, Saharinen J, Vanhala E, Karjalainen A, Hollmén J, Knuutila S, Anttila S. Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene, 2007. 26(32): p. 4730-7.
  55. Björklund M, Taipale M, Varjosalo M, Saharinen J, Lahdenperä J, Taipale J. Identification of pathways regulating cell size and cell-cycle progression by RNAi. Nature, 2006. 439(7079): p. 1009-13.
  56. Ek, Sari, Kartimo, Heikki, Mattila, Sampo, Tolonen, Ari. Characterization of phenolic compounds from Lingonberry (Vaccinium vitis-idaea). Journal of Agricultural and Food Chemistry, 2006. 54, 9834-9842.
  57. Härtter, Sebastian, Korhonen, Tuomas, Lundgren, Stefan,  Rane, Anders, Tolonen, Ari, Turpeinen, Miia, Laine, Kari. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin. Basic & Clinical Pharmacology & Toxicology, 2006. 99, 300-304.
  58. Korjamo Timo, Mönkkönen Jukka, Uusitalo Jouko, Turpeinen Miia, Pelkonen Olavi, Honkakoski Paavo. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharmaceutical Research, 2006. 23,1991-2001.
  59. Leskelä, Hannu-Ville, Olkku, Anu, Lehtonen, Siri, Mahonen, Anitta, Koivunen, Jussi, Turpeinen, Miia, Uusitalo, Jouko, Pelkonen, Olavi, Kangas, Lauri, Selander, Katri, Lehenkari, Petri. Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts. Bone, 2006. 39, 1026-1034.
  60. Mononen N, Seppälä EH, Duggal P, Autio V, Ikonen T, Ellonen P, Saharinen J, Saarela J, Vihinen M, Tammela TL, Kallioniemi O, Bailey-Wilson JE, Schleutker J. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res, 2006. 66(2): p. 743-7.
  61. Petsalo, Aleksanteri, Jalonen, Jorma, Tolonen, Ari. Identification of flavonoids of Rhodiola rosea by liquid chromatography-tandem mass spectrometry; radical fragment ions and fragment ion intensities as indicators of glycosylation sites. Journal of Chromatography A, 2006. 1112, 224-231.
  62. Turpeinen, Miia, Korhonen, Laura, Tolonen, Ari, Uusitalo, Jouko, Juvonen, Risto, Raunio, Hannu, Pelkonen, Olavi.  Cytochrome P450 (CYP) inhibition screening: Comparison of three tests. European Journal of Pharmaceutical Sciences, 2006. 29(2) 130-138.
  63. Gangal, R., Sharma, P. Human pol II promoter prediction: time series descriptors and machine learning. Nucleic Acids Res., 2005. Mar 1;33(4):13326.
  64. Lonka L, Aalto A, Kopra O, Kuronen M, Kokaia Z, Saarma M, Lehesjoki A-E. The neuronal ceroid lipofuscinosis Cln8 gene expression is developmentally regulated in mouse brain and up-regulated in the hippocampal kindling model of epilepsy. BMC Neuroscience, Apr 13:6:27, 2005.
  65. György, Zsuzsanna, Tolonen, Ari, Neubauer, Peter, Hohtola, Anja. Enhanced biotransformation capacity of Rhodiola rosea callus cultures for glycosid production. Plant Cell, Tissue and Organ Culture, 2005. 83, 129-135
  66. Korhonen, Tuomas, Tolonen, Ari, Uusitalo, Jouko, Lundgren, Stefan, Jalonen, Jorma, Laine, Kari. The role of CYP2C and CYP3A in the disposition of 3-ketodesogestrel after administration of desogestrel. British Journal of Clinical Pharmacology, 2005. 60, 69-75.
  67. Korjamo T.,  Honkakoski P., Toppinen M.R., Niva S., Reinisalo M., Palmgrén J.J., Mönkkönen J. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci., 2005. 26, 266-79.
  68. Nikali K, Suomalainen A, Saharinen J, Kuokkanen M, Spelbrink JN, Lönnqvist T, Peltonen L. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet, 2005. 14(20): p. 2981-90.
  69. Pakkasjärvi N, Gentile M, Saharinen J, Honkanen J, Herva R, Peltonen L, Kestilä M. Indicative oligodendrocyte dysfunction in spinal cords of human fetuses suffering from a lethal motoneuron disease. J Neurobiol, 2005. 65(3): p. 269-81.
  70. Pelkonen, Olavi, Turpeinen, Miia, Uusitalo, Jouko, Rautio, Arja, Raunio, Hannu. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic & Clinical Pharmacology & Toxicology, 2005. 96, 167-175.
  71. Shrivastava, Sudhir (Ed), Gangal R. Informatics in Proteomics, Chapter 10; Datamining in Proteomics, 2005. 208226. CRC Press LLC.
  72. Turpeinen, Miia, Uusitalo, Jouko, Jalonen, Jorma, Pelkonen, Olavi. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. European Journal of Pharmaceutical Sciences, 2005. 24(1), 123-132.
  73. Tolonen, Ari, Turpeinen, Miia, Uusitalo, Jouko, Pelkonen, Olavi. A simple method for differentiation of monoisotopic drug metabolites with hydrogen-deuterium exchange LC/MS. European Journal of Pharmaceutical Sciences, 2005. 25, 155-162.
  74. Turpeinen, Miia, Tolonen, Ari, Uusitalo, Jouko, Jalonen, Jorma, Pelkonen, Olavi, Laine, Kari. Effect of clopidrogel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clinical Pharmacology & Therapeutics, 2005.  77(6), 553-559.
  75. Tolonen, Ari, Lehto, Tiina, Hannuksela, Minna, Savolainen, Markku. A method for determination of phosphatidylethanol from high density lipoproteins by reversed phase HPLC with TOF-MS detection. Analytical Biochemistry, 2005. 341, 83-88.